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Human cells express fourmitochondrial adenine nucleotide translocase (hANT)
isoforms that are tissue-specific and developmentally regulated. hANT1 is
mainly expressed in terminally differentiated muscle cells; hANT2 is growth-
regulated and is upregulated in highly glycolytic and proliferative cells; and
hANT3 is considered to be ubiquitous and non-specifically regulated. Here,
we studied how the expression of hANT isoforms is regulated by proliferation
and in response tometabolic stimuli, and examined themetabolic consequences
of their silencing and overexpression. In HeLa and HepG2 cells, expression of
hANT3 was upregulated by shifting metabolism towards oxidation or by
slowed growth associated with contact inhibition or growth-factor deprivation,
indicating that hANT3 expression is highly regulated. Under these conditions,
changes in hANT2 mRNA expression were not observed in either HeLa
or HepG2 cells, whereas in SGBS preadipocytes (which, unlike HeLa and
HepG2 cells, are growth-arrest-sensitive cells), hANT2mRNA levels decreased.
Additionally, overexpression of hANT2 promoted cell growth and glycolysis,
whereas silencing of hANT3 decreased cellular ATP levels, limited cell growth
and induced a stress-like response. Thus, cancer cells require both hANT2 and
hANT3, depending on their proliferation status: hANT2 when proliferation
rates are high, and hANT3 when proliferation slows.
1. Background
Adenine nucleotide translocase (ANT) is an integral inner mitochondrial
membrane protein that counter-exchanges newly synthesized ATP in the mito-
chondrial matrix for cytosolic ADP, allowing the proper function of oxidative
phosphorylation (OXPHOS; for a review, see [1]). In addition to this classical trans-
port function, several lines of evidence indicate that ANT is also involved in other
cellular activities. For example, ANT plays a role in mitochondrial proton leakage
[2] and has long been proposed to participate directly in the mitochondrial
transition pore [3], although this role now seems to be more indirect [4,5].
Several genes encode ANT isoforms in the vast majority of organisms, from
yeast to humans. In humans, there are four ANT isoforms that exhibit cell- and
tissue-specific expression [6–8]. Human ANT1 (hANT1) is prominently expressed
in highly oxidative cells of muscle lineage, such as skeletal muscle and heart, but is
also expressed in other highly oxidative tissues, such as the brain. hANT1 is the iso-
form that best fits the classical ANT function in theOXPHOSprocess because it is in
these organs (heart, skeletal muscle and brain) that OXPHOS is most active [9]. The
hANT2 isoform is generally expressed at low levels except in tissues with high
regenerative activity, such as liver and highly proliferative blood cells [10]; impor-
tantly, it is upregulated in many cancer cells [11,12]. hANT2 was first cloned in
human fibroblasts as an early response gene [10], and it has been described as a
marker of cell proliferation [13]. These characteristics, taken together with the
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2observation that hANT2 is upregulated when OXPHOS activity
is generally low, suggest that this isoform may serve functions
other than a classic OXPHOS function. Accordingly, it has
been proposed that hANT2 is responsible for mitochondrial
ATP uptake [14], working in a reverse mode to fuel themultiple
mitochondrial energy-dependent activities that this organelle
performs. This process is especially relevant in highly glycolytic
cells, suchasproliferative cancercells. ThehANT3 isoform isubi-
quitously expressed. As such, its gene expression has not been a
focus of research, although some attempts have been made to
elucidate its regulation. In this context, we have reported that
hANT3 expression, as well as that of the other isoforms, is regu-
lated by PGC-1a (peroxisome proliferative activated receptor-g
coactivator 1a) through different transcription factors [15].
hANT3 is predicted to serve a classic OXPHOS function in tis-
sues other than heart and skeletal muscle, where the hANT1
isoform represents themajor fraction of total translocase activity
[16]. Finally, expression of the hANT4 isoform is restricted to
male germinal cells, although residual expression of ANT4 has
been detected in other tissues, such as liver [7].
A close relationship has also been established between indi-
vidual human ANT isoforms and the regulation of apoptosis.
Accordingly, it has been reported that hANT1 overexpression
in cultured cells induces apoptosis predominantly through
the intrinsic pathway [17,18]. As hANT2 is prominently associ-
ated with proliferative cells, this isoform has been considered
anti-apoptotic. In support of this, knockdown of hANT2 sensi-
tizes cells to lonidamine-induced apoptosis [12], and hANT2
knockout induces apoptosis and inhibits tumour growth,
both in vitro and in vivo [19]. Finally, as is the case for
hANT1, we have described that hANT3 overexpression
induces apoptosis in vitro through the regulation of mPTP
(mitochondrial permeability transition pore) activity [20].
Although it seems well established in the literature that
expression of the hANT2 gene is highly regulated, whereas
the hANT3 gene is ubiquitously expressed, our studies on
cells in culture suggest a more nuanced view of the regulation
of these isoforms. Because the expression of hANT isoforms
seems to be particularly sensitive to themetabolic and prolifera-
tive status of cells, we have undertaken an extensive studyof the
differentialmRNAexpression of hANT1–3 isoformsunder var-
ious proliferative conditions and in response to different
metabolic stimuli in human cell lines. In an attempt to discern
the functions of specific hANT isoforms, we have also investi-
gated the effects of overexpression and silencing of hANT2
and hANT3 on cell growth andmetabolism. Our results clearly
demonstrate that hANT3 is the main isoform regulated by pro-
liferative and metabolic stimuli in HeLa and HepG2 cells, cell
lines characterized by not being fully susceptible to growth
arrest (i.e. in response to growth-factor deprivation or cell con-
tact). hANT3 is also essential for cell growth, and its silencing
results in energy impairment and a cell stress-like response.
On the other hand, hANT2by itself is able to induce cell prolifer-
ation and shift cell metabolism towards glycolysis. Thus, both
hANT2 and hANT3 are essential for cancer cells.2. Methods
2.1. Cell culture
Human HeLa and HepG2 cells were cultured in maintenance
medium composed of Dulbecco’s Modified Eagle Medium(DMEM) supplemented with 10% (v/v) fetal bovine serum
(FBS) and 100 units ml21 penicillin/streptomycin (P/S) (all
from Gibco/Life Technologies, Foster City, CA, USA) at 378C
in a humidified 95% air/5% CO2 incubator. Human SGBS pre-
adipocytes were grown in Medium A consisting of DMEM
containing 10% FBS, 1% P/S, 33 mM biotin, and 17 mM pan-
tothenic acid (Sigma-Aldrich) at 378C in a humidified 95%
air/5% CO2 incubator. For proliferation studies, cells were
plated in 6-well plates at low density (LD; 5  104 cells well21)
or high density (HD; 5  105cells well21). Medium was chan-
ged every 24 h. HeLa cells plated at LD were treated with
rapamycin (20 or 100 nM, as indicated; Sigma-Aldrich,
St Louis, MO, USA) or DMSO (vehicle) for 24 h.
2.2. Reagents
Dimethyl sulfoxide (DMSO), oligomycin, N-acetylcysteine
(NAC), antimycin A, lonidamine and staurosporine were
obtained from Sigma-Aldrich.
2.3. Transient transfection with shRNA
shRNA for specific knockdown of hANT2 (shANT2, 50-CTG
TTGCCGGGTTGACTTCC-30) and hANT3 (shANT3, 50-CGC
GACCTCCCTCTGCTTCG-30), and scrambled control shRNA
(shANTm, 50-CGGATCGCTACAAATAAG-30), were construc-
ted using a BLOCK-iT U6 RNAi Entry Vector Kit (Invitrogen/
Life Technologies, Foster City, CA, USA). For transient trans-
fections, cells were plated in 6-well plates and then
transfected 24 h later using the FuGENE HD Transfection
Reagent (Promega, Madison, WI, USA) as described by the
manufacturer. Briefly, the required amount of plasmid was
mixed with FuGENE and Opti-MEM (Invitrogen/Life Tech-
nologies), and the mix was dispensed into cell media and
incubated with cells for 48 h. A transfection efficiency greater
than 80% was routinely achieved.
2.4. Adenoviral transduction
After plating cells in 6-well plates and inducing differentiation
if required, cells were transduced at different multiplicities of
infection (MOIs) for 48 hwith distinct adenoviruses containing
expression constructs for GFP (transduction control), hANT2
or hANT3. Adenoviruses were obtained from the Center for
Animal Biotechnology and Gene Therapy (CBATEG, Universi-
tat Auto`noma de Barcelona, Bellaterra, Spain). Adenovirus
transduction was carried out by mixing the volume of adeno-
virus needed with 0.5 mlwell–1 of DMEM containing
0.5 mg ml–1 poly-L-lysine (Sigma-Aldrich), added to enhance
the efficiency of transduction. After removing maintenance
or differentiation media and washing cells with 1 phos-
phate-buffered saline (PBS), the adenovirus mix was added
into each well and plates were incubated for 5 h at 378C in a
humidified 95% air/5% CO2 incubator with regular rocking.
Thereafter, wells were filled with regular media (2 ml well21)
appropriate for each cell line.
2.5. RNA isolation, cDNA synthesis and quantitative
real-time PCR
Total RNA from cultured cells was isolated using a column-
affinity-based method (NucleoSpin RNA II; Macherey-Nagel,
Du¨ren, Germany). cDNA was synthesized from 500 ng of
total RNA using Multiscribe reverse transcriptase and
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3random-hexamer primers (TaqMan Reverse Transcription
Reagents from Applied Biosystems/Life Technologies,
Foster City, CA, USA). For mRNA expression analyses,
TaqMan quantitative real-time PCR (qPCR) was performed on
a 7500 Real-Time PCR System (Applied Biosystems) in a final
volume of 20 ml using Platinum Quantitative PCR SuperMix-
UDG with ROX reagents (Invitrogen/Life Technologies) and
the following primer pair/probe sets specific for the indicated
human targets: CCL2 (MCP1), Hs00234140_m1; DDIT3
(CHOP10), Hs00358796_g1; HSPA5, Hs00607129_gH; IL6,
Hs00174131_m1; PDK4, Hs00176875_m1; SLC25A4 (hANT1),
Hs00154037_m1; SLC25A5 (hANT2), Hs00854499_g1;
SLC25A6 (hANT3), Hs00745067_s1; tumour necrosis factor-a
(TNF-a), Hs00174128_m1; and 18S rRNA, Hs99999901_s1
(TaqMan Gene Expression Assays; Applied Biosystems). The
relative levels of target mRNA expression were normalized to
that of 18S rRNA, used as an endogenous control.
2.6. DNA isolation and quantification of mtDNA content
Total DNA was isolated from cultured cells by phenol/
chloroform extraction. Mitochondrial DNA (mtDNA) was
quantified by real-time PCR amplification of 100 ng of total
DNA using a cytochrome b (MT-CYTB) primer/probe set
(Hs02596867_s1). The results were expressed relative to
the quantity of nuclear DNA, which was determined by
amplification of the intronless gene CEBPa (Hs00269972_s1).
2.7. Analysis of proliferation by sulforhodamine B
colorimetric assay
Cell density was determined by measuring cellular protein con-
tent using the sulforhodamine B (SRB) colorimetric assay [21].
At the indicated times, cells were washed with PBS, fixed with
10% (w/v) trichloroacetic acid for 1 h at 48C, and stained with
0.4% (w/v) SRB in 1% (v/v) acetic acid for 20 min. After remov-
ing excess dye by washing several times with 1% (v/v) acetic
acid, stained protein was dissolved in 10 mM Tris-based
solution for spectrophotometric determination at 550 nm.
2.8. Analysis of proliferation by cell counting
Cell countingwasused as an alternativemethod for determining
cell proliferation. At the indicated times, cells were washed
with PBS, detached from culture plates by incubating with
200 ml well21 of 0.05% trypsin-EDTA (Gibco) at 378C for
2 min, and collected in 2 mlwell21 of DMEM. After exclusion
staining with 0.4% Trypan Blue (Gibco), cells were counted
usingaCountessAutomatedCellCounter platform (Invitrogen).
2.9. Analysis of proliferation by DNA content
Total DNA from cultured cells was isolated using a phenol/
chloroform extraction method, and DNA concentration was
measured using a NanoDrop ND-1000 Spectrophotometer
(NanoDrop Technologies, Wilmington, DE, USA).
2.10. Determination of glucose and lactate in cell
culture medium
Glucose and lactate concentrations at each plating density
were quantified in cell culture medium collected every 24 h.Glucose concentration was determined spectrophoto-
metrically at 340 nm using the Glucose Assay Reagent
(Sigma-Aldrich). Lactate concentration determination is
based on the L-lactate-to-pyruvate transformation mediated
by L-lactate dehydrogenase (Roche Diagnostics GmbH, Man-
nheim, Germany) in the presence of NADþ, with subsequent
spectrophotometric quantification of the NADH co-product
at 340 nm. Both glucose consumption and lactate production
are expressed as the difference in the concentration in
medium every 24 h normalized to cellular protein content,
determined by SRB assay at the corresponding time point.
2.11. Determination of D-glucose oxidation
Glucose oxidation was measured using radiolabelled
[14C(U)]-D-glucose (HartmannAnalytic GmbH, Braunschweig,
Germany) as described by the manufacturer. Briefly, cells
plated at the indicated densities were grown for 48 h and incu-
bated with DMEM (without D-glucose) supplemented with
3 mM D-glucose and 1.5 mCi ml
21 [14C(U)]-D-glucose for 3 h
at 378C in a 5% (v/v) CO2 atmosphere. Labelled
14CO2 was
then released from the medium by acidification with 3 M
HClO4 and retained in a CO2 trap consisting of Whatman
3 MM Chr paper (Whatman, GE Healthcare, Little Chalfont,
UK) impregnated with B-phenylethylamine (Sigma) and posi-
tioned over the wells inside the sealed plates. After 1 h, CO2
traps were placed in scintillation vials containing 10 ml
of scintillation fluid, and the samples were counted using a
Packard 2100TR TriCarb Liquid Scintillation Counter (Packard
Instrument Company Inc., Meriden, CT). Decays per minute
were normalized to cellular protein content determined by
SRB assay.
2.12. Quantification of cellular ATP
Cells were washed with PBS, and cellular ATP content was
determined using an ATP Bioluminescence Assay Kit (HS
II; Roche Diagnostics GmbH). Bioluminescence was
measured using a Glomax luminometer (Promega). ATP
values were expressed relative to total protein concentration,
previously quantified in cell lysates using the Bradford
method (Bio-Rad Protein Assay; Bio-Rad Laboratories
GmbH, Munich, Germany).
2.13. Quantification of cytokines in cell culture medium
TNF-a, IL6 andMCP-1 protein levels accumulated inHeLa cell
culture media 48 h after transfection with shANTm, shANT2
or shANT3 were measured using the MILLIPLEX MAP kit
HADCYT-61 K, based on Luminex xMAP multiplexing
technology (Millipore Corporation, Billerica, MA, USA).
2.14. Protein extraction and Western blotting
Total cell homogenates were prepared by scraping cells in
100 ml well21 of homogenizing buffer (20 mM Na-HEPES
pH 7.4, 2.5 mM NaCl, 1 mM EDTA, 40 mM b-glyceropho-
sphate, 2 mM Na3VO4, 1% NP-40, 1 mM PMSF, 1 mM DTT,
one tablet complete protease inhibitor cocktail per 10 ml of
buffer; Roche Applied Science), and incubated at 48C with
agitation for 45 min. Lysates were centrifuged at 12 000g at
48C for 5 min to remove membrane fragments. Supernatant
protein concentration was quantified using the Bradford
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4method (Bio-Rad Protein Assay). Mitochondria-enriched and
cytosolic protein fractions were prepared by collecting cells in
100 ml well21 of homogenizing buffer (250 mM sucrose,
20 mM Na-HEPES pH 7.4, 10 mM KCl, 1.5 mM MgCl2,
1 mM EDTA, 1 mM EGTA, 40 mM b-glycerophosphate,
2 mM Na3VO4, 1 mM PMSF, 1 mM DTT, one tablet complete
protease inhibitor cocktail per 10 ml of buffer; Roche Applied
Science) and homogenized in an ice-cold Dounce-type glass
homogenizer (50 strokes). Lysates were centrifuged at 1500g
for 5 min at 48C to remove intact cells, and supernatants
were centrifuged again at 16 000g for 20 min at 48C to
obtain a cytosolic fraction (supernatant) and a mitochon-
dria-enriched fraction (pellet). Protein was quantified using
the Bradford method (Bio-Rad Protein Assay). For Western
blotting, 40 mg of protein was heated for 5 min at 958C
under reducing conditions and then resolved by SDS-PAGE
on 12% gels for 3 h at a constant voltage of 100 mV. Proteins
were transferred electrophoretically to PVDF membranes
(Immobilon; Millipore, Billerica, MA, USA) for 1 h at a con-
stant amperage of 400 mA, and then blocked in 1 PBS
containing 5% (wt/vol) non-fat milk and 1% Tween-20
(Sigma-Aldrich) for 1 h at room temperature with agitation.
Afterwards, membranes were incubated with primary anti-
bodies against ANT (N-19) (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), OPA-1 (Abcam, Cambridge, UK),
a-tubulin (Sigma-Aldrich) or VDAC (Calbiochem, La Jolla,
CA, USA) diluted in 1 PBS containing 3% (wt/vol) non-
fat milk and 0.1% Tween-20 overnight at 48C with agitation.
After incubation with horseradish peroxidase (HRP)-coupled
secondary antibody (diluted in 1 PBS containing 3%
(wt/vol) non-fat milk and 0.1% Tween-20) for 1 h at room
temperature with agitation, immunoreactive proteins were
detected using a chemiluminescent HRP substrate (Millipore)
and a Luminescent Image Analyzer LAS-3000 (Fujifilm Life
Science, Tokyo, Japan). Signals were quantified using MULTI
GAUGE software (Fujifilm).
2.15. Quantification of reactive oxygen species
Reactive oxygen species (ROS) levels were quantified by
fluorometry using an OxiSelect Intracellular ROS Assay
Kit (Green Fluorescence) (Cell Biolabs Inc., San Diego,
CA, USA). Briefly, after removing media and washing with
1 PBS, cells were incubated with 0.1 2,7-dichlorodihydro-
fluorescein diacetate (DCFH-DA) in DMEM at 378C for 1 h.
Labelling medium was removed and cells were washed and
lysed with 1 Cell Lysis Buffer (provided with the kit)
for 5 min with agitation. The fluorogenic activity of DCF
(generated by the oxidation of DCFH by ROS) in cell lysates
was measured using a FLUOstar OPTIMA microplate fluo-
rometer (BMG Lab Technologies, Durham, NC, USA).
Absorbance values were expressed relative to protein content
in cell lysates.
2.16. Statistical analysis
All results are expressed as means+ s.e.m., and differences
were analysed for statistical significance using unpaired
t-test, one-way analysis of variance (ANOVA) with Tukey’s
multiple comparison test or two-way ANOVA with Bonfer-
roni post hoc test, as appropriate. Significance of differences
is reported at p, 0.05, p, 0.01 and p, 0.001 levels, as
indicated in figure legends.3. Results
3.1. mRNA expression of hANT isoforms in HeLa cells
under proliferative and cell-arrest conditions
To analyse the changes in hANT isoform mRNAs in cells
stimulated to proliferate or undergo growth arrest, we plated
HeLa cells at HD or LD and allowed them to grow for 96 h.
As depicted in figure 1a, HD cells reached confluence after
48 h in culture, indicating that they were sensitive to cell con-
tact-dependent growth arrest. By contrast, LD cells grew
continuously until 96 h, at which point they reached the
same confluent endpoint as HD cells. We chose 48 h of culture,
when HD cells had stopped growing and LD cells were still
proliferating, as the time for studying metabolic-dependent
differences in the expression of hANT isoforms. At this time
point, LD cells were more glycolytic, as evidenced by their
greater consumption of glucose and production of lactate,
and reduced rate of glucose oxidation compared with HD
cells (figure 1b–d). HeLa cells expressed all three hANT iso-
forms; hANT2 and hANT3 were expressed at similar levels,
whereas hANT1, the muscle-specific isoform, was expressed
at lower levels (figure 1e–g). In growth-arrested (HD) cells,
hANT1 expression decreased slightly, hANT2 did not change
and hANT3 expression significantly increased compared
with proliferating (LD) cells (figure 1e–g). Exploiting the dis-
tinct putative role of hANT2 in glycolytic metabolism
comparedwith the function of hANT1 and hANT3 in oxidative
metabolism, we developed an ANT glycolytic index, defined
as the hANT2 mRNA/(hANT1 mRNA þ hANT3 mRNA)
ratio. We found that the ANT glycolytic ratio was lower in
oxidative/growth-arrested (HD) cells than in glycolytic/
proliferative (LD) cells (figure 1h). Interestingly, adaptive
changes in the ANT glycolytic ratio were attributable to
changes in the hANT3 isoform in HeLa cells, previously
defined as ubiquitous, indicating that the regulation of this
isoform is more important than previously assumed.3.2. A decrease in the ANT glycolytic ratio is associated
with a metabolic shift towards oxidation in HepG2
and SGBS cells
To determine whether the regulation of hANT3 mRNA was
restricted to HeLa cells, we expanded these studies to other
human cell lines with or without susceptibility to cell-arrest
regulation. To this end, we used HepG2 cells, a hepatocyte cell
line derived from a human hepatocellular carcinoma that is
not fully susceptible to cell contact-dependent cell arrest. We
observed thatHepG2cells platedatHDandLDwere able to con-
tinuously proliferate for at least 96 h (figure 2a).When cellswere
plated under HD conditions, their growth slowed but did not
stop. In addition to the decrease in the rate of growth, cells
plated under HD conditions showed a metabolic shift towards
oxidation at 72 h after seeding, as indicated by a decrease in glu-
cose uptake (figure 2b) and lactate production (figure 2c). These
alterations in growth rate and the concomitant metabolic shift
were accompanied by a marked increase in hANT3 mRNA
expression (figure 2f), a small decrease in hANT1 (figure 2d)
and no changes in hANT2 (figure 2e). Thus, hANT3 mRNA
expression was increased in slow-growing HepG2 cells that
had acquired an oxidative metabolism, resulting in a decrease
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Figure 1. Non-proliferating HeLa cells show an increase in oxidative metabolism and hANT3 mRNA expression. (a) HeLa cells were plated at LD and HD, and cell
growth was quantified every 24 h for 4 days by determining total protein in fixed cells using SRB assays. (b–d) Quantification of (b) glucose consumption, (c) lactate
production and (d ) glucose oxidation by HeLa cells under LD and HD conditions 48 h after seeding. (e–h) Determination of (e) hANT1, ( f ) hANT2 and (g) hANT3
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5in the ANT glycolytic index (figure 2g). Wewere also interested
in studying the mRNA expression profile of ANT isoforms
under proliferative and growth-arrest conditions in cells of a
fibroblastic lineage, where hANT2 was first described as a cell
proliferation marker [13]. For this purpose, we used SGBS
cells, a human preadipocyte cell line fully susceptible to
growth arrest [22]. SGBS cells grew at a slow rate even when
plated at LD (figure 2h). At 96 h of culture, LD cells were still
proliferating, whereas HD cells had already reached confluence
and stopped growing. Similar to HeLa and HepG2 cells, SGBS
cells under HD conditions also showed a decrease in glucose
uptake (figure 2i) and lactate production (figure 2j). SGBS cells
expressed approximately three times more hANT3 than
hANT2 mRNA, and presented very low levels of hANT1
mRNA (figure 2k–m), a result in accordwith themore oxidativemetabolic profile of this preadipocyte cell compared with the
highly proliferative, glycolytic HeLa and HepG2 cells. Cell
growth arrest produced a marked decrease in hANT2 mRNA,
with no change in hANT3 or hANT1 mRNA. This resulted in
a decrease in the ANT glycolytic ratio (figure 2n), indicating a
shift to a more oxidative metabolism upon growth arrest. In
this case, however, the change in the ANT glycolytic ratio was
attributable to changes in hANT2 isoform mRNA expression.3.3. mRNA expression of hANT isoforms in HeLa cells
under oxidative/glycolytic conditions
To further study the relationship between the shift in glycolytic
to oxidative metabolism and the expression of hANT isoforms,
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6we incubated HeLa cells in media containing the non-
fermentable substrate glutamine (GLN cells) without glucose
or in complete medium (CTRL cells) containing both high
glucose and glutamine [23,24]. The aim of this experiment
was to force cells to acquire an oxidative metabolism (GLN
cells) or shift metabolism towards glycolysis (CTRL cells).
GLN cells incubated for 24 and 48 h stopped growing
(figure 3a) and markedly reduced their production of lactate
(figure 3b); when pulsed with glucose at 48 h of culture, they
doubled their rate of glucose oxidation compared with CTRL
cells (figure 3c), indicating a metabolic shift towards oxidativemetabolism. The oxidative phenotype of GLN cells was further
demonstrated by their strict dependence on OXPHOS for the
maintenance of cellular ATP levels. As can be seen in
figure 3d, CTRL cells maintained their ATP concentration in
the presence of oligomycin, an ATP synthase inhibitor, indicat-
ing that they fulfilled their energy requirements mainly
through glycolysis. By contrast, GLN cells were highly sensi-
tive to oligomycin, indicating their dependence on OXPHOS.
In this situation, hANT isoformmRNA levels changed accord-
ingly: hANT1 and hANT2 mRNA showed only minor
changes, whereas hANT3 mRNA markedly increased at both
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824 and 48 h (figure 3e–g), resulting in a decrease in the ANT
glycolytic ratio (figure 3h). Again, it was the expression of the
hANT3 isoform that showed major changes.
3.4. Effects of growth factors and inhibition of growth-
factor signalling on mRNA expression of hANT
isoforms in HeLa cells
Cell proliferation is dependent on growth factors. Accordingly,
we sought to determine how growth factors affected the
expression of hANT isoforms. To accomplish this, we incu-
bated HeLa cells with or without FBS for 72 h. As shown in
figure 4a, HeLa cells were only partially sensitive to FBS.
Although they proliferated more in the presence of 10% FBS,
they were nonetheless able to grow in the absence of FBS and
thus were not fully susceptible to serum deprivation-induced
growth arrest (figure 4a). FBS did not affect the expression of
hANT2 or hANT1 mRNA (figure 4b,c), but did suppress
hANT3 mRNA expression (figure 4d ). Thus, growth factors
present in FBS increased the ANT glycolytic ratio (figure 4e).
To gain insight into the regulation of hANT3 by a prolifera-
tive stimulus, we treated proliferating HeLa cells, plated at LD,
with two different concentrations of rapamycin (20 or 100 nM),for 24 h. This compound is a known inhibitor of mTOR, a
factor that lies at a crucial point in the integration of molecular
signals induced by growth factors [25]. Inhibition of mTOR by
rapamycin decreased cell proliferation (figure 4f ), slightly
downregulated both hANT1 and hANT2 expression, an
effect that showed inconsistent concentration dependence,
but substantially increased the expression of hANT3 mRNA
(figure 4g– i), resulting in a decrease in the ANT glycolytic
ratio (figure 4j). However, the possibility that the changes in
hANT3 mRNA levels induced by rapamycin treatment were
attributable to factors other than inhibition of cell proliferation
cannot be discounted.
3.5. Overexpression of hANT2 induces cell growth and
glycolytic metabolism
Having established that the expression of distinct hANT iso-
forms is regulated in a manner that depends on the metabolic
and/or proliferative status of the cells, we sought to investi-
gate the proliferative and metabolic consequences triggered
by changing the relative expression of hANT2 and hANT3
isoforms. We first addressed this issue by overexpressing
hANT2 and hANT3 in HeLa cells. Adenoviral transduction
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9at an MOI of 50 for 48 h was sufficient to obtain adequate
hANT2 overexpression compared with GFP transduced
cells (transduction control), as determined by mRNA and
protein expression (figure 5a). We also validated that over-
expressed hANT2 protein was localized to mitochondria
(figure 5b) and that overexpression of hANT2 did not affect
the expression of hANT3 mRNA (figure 5c). Overexpression
of hANT2 in HeLa cells using these optimized transduction
conditions increased cell growth at 96 h after transduction
(figure 5d ). HeLa cells overexpressing hANT2 also exhibi-
ted increased glucose consumption (figure 5e) and lactate
production (figure 5f ), indicating enhanced glycolytic
metabolism. Under these conditions, ATP levels were not
affected (figure 5g), suggesting that this change in glucose
metabolism did not compromise the energy status of HeLa
cells. On the contrary, overexpression of hANT3 stopped
cell growth, in accordance with our previous observation
that hANT3 overexpression in cultured cells promotes apop-
tosis [20]. Overexpression of hANT2 in HepG2 cells also
triggered a shift from oxidative to glycolytic metabolism
(data not shown).
3.6. Silencing of hANT2 and hANT3 isoforms
As a complement to hANT2-overexpression approaches, we
also studied the effects of changing the relative expression of
hANT2 and hANT3 in HeLa cells by isoform-specific silencingusing shRNA-mediated knockdown to better understand
the role of specific ANT isoforms in metabolism. As shown
in figure 6a,b, isoform-specific shRNAs effectively silenced
hANT2 and hANT3 at themRNA level, resulting in a concomi-
tant reduction in hANT3 protein, but only amodest decrease in
hANT2 protein. hANT2 knockdown did not affect cell growth
(figure 6c), most probably because of its minimal effects on
protein expression. However, hANT2 silencing did reduce lac-
tate production and increase glucose oxidation (figure 6d–f ),
demonstrating a direct role of the hANT2 isoform in regulating
oxidative metabolism. This metabolic adaptation did not
change the energy status of cells, as indicated by the mainten-
ance of ATP levels (figure 6g). On the other hand, cellswith low
levels of hANT3 expression completely stopped cell growth
(figure 6c) and were unable to shift their metabolism towards
a more glycolytic state (figure 6d– f), resulting in a significant
decrease in intracellular ATP levels indicative of an impaired
energy status (figure 6g). It is likely that this lack of sufficient
ATP is responsible for preventing cell growth. These results
demonstrate that hANT3 is essential in slow-proliferating
HeLa cells.
3.7. Silencing of hANT3 induces a cell stress response
The inability of HeLa cells to compensate for hANT3 silencing
at the energy level prompted us to investigate how cells sensed
the decrease in hANT3 function. To this end, we studied
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10cytokine production as an indicator of cell stress response [26].
Silencing of hANT2 had no effect on the expression of cyto-
kines; importantly, hANT3 knockdown significantly induced
the expression of TNF-a, IL6 and MCP-1 in HeLa cells
(figure 7a). This induction in mRNA levels correlated with an
increase in the protein levels of IL6 and MCP-1 in cell culture
media (figure 7b). However, the levels of TNF-a protein were
below the lower limits of detection of the method used.
shRNA-mediated hANT3 knockdown did not result in an
increase in the levels of ROS (figure 7c), known intermediates
in the cytokine production response [27], whereas antimycin
A, a known ROS inducer [28], did induce ROS production,
indicating the functionality of this pathway in HeLa cells.
Moreover, pretreatment with the antioxidant NAC did not
suppress the induction of TNF-a expression in hANT3-
knockdown HeLa cells (figure 7d ), as NAC did with the cells
treated with antimycin A. Collectively, these results indicate
that ROS did not mediate the stress response associated with
hANT3 knockdown in HeLa cells. Another recognized inter-
mediate in the stress response is ER stress [29]. The induction
of cytokine expression by hANT3 silencing also did not
appear to involve an ER stress response, as evidenced by the
lack of changes in expression of the ER stress markers HSPA5
and CHOP10 under these conditions (figure 7e). Finally, we
investigated the possible participation of mitochondrial stress
as an inducer of cellular stress [30]. First, we analysed the
levels of OPA1, a protein involved in mitochondrial fusion.Under mitochondrial stress situations, the long form of OPA1
(L-OPA1) is totally proteolysed to the short form (S-OPA1),
impairing mitochondrial fusion and inducing mitochondrial
fragmentation [31]. hANT3-knockdown HeLa cells showed no
accumulation of the stress-induced S-OPA1 form, which if any-
thing trended lower (figure 7f). Likewise, mitochondrial stress
has also been associated with an increase in mtDNA content
[32]. Neither hANT2 nor hANT3 knockdown in HeLa cells pro-
duced an increase in mtDNA content, instead slightly
decreasing it (figure 7g). Thus, hANT3 silencing seemed not to
result in significant mitochondrial stress. Furthermore, neither
hANT2 nor hANT3 silencing triggered significant changes in
mitochondrial membrane potential (data not shown).
Having eliminated a role for ROS production, ER stress
and mitochondrial stress in the stress response triggered by
hANT3 silencing, we considered the possible involvement of
the decrease in ATP levels. To test this, we treated confluent
HeLa cells with 10 mM oligomycin, an ATP synthase inhibitor.
As expected, since in these conditions HeLa cells are
oxidative (figure 1), oligomycin created an energy failure situ-
ation, as demonstrated by a dramatic decrease in ATP levels
(figure 7h). Interestingly, the decrease in ATP levels was
accompanied by an increase in IL6 expression (figure 7i). This
effect was completely independent of ROS production, as
demonstrated by the failure of NAC to alter oligomycin-
induced IL6 gene expression and the fact that ROS levels
were even lower in oligomycin-treated HeLa cells (figure 7j).
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11Collectively, these results suggest that the induction of cytokine
production by a decrease in hANT3 is not mediated by an
increase in ROS production. Hence, it is reasonable to conclude
that the cell stress response induced by hANT3 silencing could
be induced by a decrease in the energy status of cells.4. Discussion
The principal finding of this study is that hANT3 is the main
regulated hANT isoform in HeLa and HepG2 cells, which
are not fully sensitive to growth factor deprivation or inhi-
bition of growth by cell contact, respectively. hANT3 was
upregulated by the induction of growth arrest as well as byforced acquisition of an oxidative metabolism. Whether
hANT3 regulation is related specifically to one of these two
processes is not known, but both processes—proliferation
and glycolytic metabolism—appear to be intimately and
mechanistically related to each another [33]. By contrast, in
SGBS preadipocytes, which are fully susceptible to growth
arrest, hANT3 expression remained stable; instead, it was the
hANT2 isoform that became growth-regulated. It has long
been recognized that hANT2 expression is highly regulated.
hANT2 was first cloned as an early response gene in human
diploid fibroblasts [10] and is considered a marker of cell pro-
liferation [13]. The promoter of the ANT2 gene has been
extensively studied, mainly by Nelson and colleagues, who
identified the promoter regions responsible for gene silencing
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12in quiescence [34], and also by Stepien and co-workers, who
described a GRBOX in the ANT2 gene promoter that is
involved in linking high glycolysis to upregulation of this
gene [14]. Our results showed that this sensitivity of hANT2
to glycolysis and proliferation is not a general phenomenon,
but instead is cell specific. Unlike the relatively well-defined
regulatory features of the hANT2 gene, there is scant knowl-
edge about the regulation of hANT3 expression. Typical of
the so-called housekeeping genes, the promoter region of the
hANT3 gene lacks TATA and CAT boxes, and has multiple
SP1-binding sites [35], presumably dampening enthusiasm
for more extensive studies. Additionally, a recent bioinfor-
matics study on the regulation of hANT isoforms expression
that compared common characteristics of the proximal promo-
ter regions of other genes with those in each of the human
ANT isoforms failed to detect a pattern of genes that were
co-regulated with hANT3, a result in line with the ubiquitous
expression of this isoform and apparent absence of a require-
ment for specific regulation [36]. Nevertheless, our results
suggest that the expression of hANT3 may be as highly
regulated as that of hANT2. Interestingly, the regulation of
hANT2 and hANT3 expression was mutually exclusive and
highly cell-type-dependent.
The fact that all species tested to date, from yeast to mam-
mals, have several ANT isoforms with specific regulated
expression and tissue-specific expression patterns [6–8]
strongly suggests specific roles and/or properties of the differ-
ent isoforms. Several lines of evidence support this conclusion.
For example, hANT1 expression is restricted to tissues with
high OXPHOS activity, like heart, muscle and brain, whereas
hANT3 is the main hANT isoform in oxidative non-muscle tis-
sues. Accordingly, hANT1 and hANT3 appear to be directly
involved in OXPHOS, acting as classic ATP/ADP translocases
to export newly produced ATP synthetized by mitochondrial
ATP synthase and import ADP from the cytosol to facilitate
its rephosphorylation. Our demonstration that hANT3
expression is upregulated in HeLa and HepG2 cells upon a
metabolic shift to oxidation highlights the oxidative role of
this isoform. By contrast, hANT2 is induced in tissues with a
high regenerative capacity (e.g. liver) and in proliferating
cells (e.g. embryonic, blood cells and cancer cells) [6–8,10]
characterized by low OXPHOS activity and high glycolysis,
even in the presence of oxygen (Warburg effect) [37]. This
expression pattern points to a special role for this isoform in
the context of OXPHOS. Specifically, it has been proposed
that hANT2 may preferentially exhibit reverse ATP/ADP
activity that would fuel mitochondria with ATP produced by
glycolysis [14].
Taking into account the opposite roles of ANT isoforms in
oxidative/glycolytic metabolism, we considered that a ratio of
the expression of hANT isoforms would be more closely
related to cell conditions than the expression of individual
hANT isoforms. Hence, we proposed an index, the ANT glyco-
lytic index, based on mRNA levels of glycolytic ANT isoform
divided by the mRNA levels of oxidative isoforms (hANT2
mRNA/(hANT1 mRNA þ hANT3 mRNA)). Our goal was to
determine whether changes in this ratio were a leading indi-
cator of glycolytic/oxidative status (or the closely related
proliferative/growth-arrest status) of cells and thus could be
used as a facile method for predicting cell status. Our results
have clearly shown that this index did accurately reflect
changes in the proliferation/quiescence and glycolytic/oxi-
dative status of cells regardless of the specific hANT isoformchanging—hANT2 in some cases, but hANT3 in others. In
any case, the meaning of the ANT glycolytic index remains
the same: it increases when cells proliferate and shift their
metabolism towards glycolysis, and decreases when cells
stop growing and shift their metabolism towards oxidation.
Thus, by calculating this index under different cellular con-
ditions, it should be possible to predict changes in the
metabolic/proliferative status of cells. Nonetheless, further
analysis in a wider spectrum of human cell lines should be
done to validate this index.
We also studied the metabolic consequences of manipulat-
ing the expression of hANT2 and hANT3 isoforms. Our results
indicate that hANT2 overexpression in HeLa cells promotes
glycolysis and also increases cell growth, findings in agreement
with the previous observation that glycolytic metabolism
can induce proliferation [38], and with the original description
of hANT2 as an early response gene and proliferation marker
[10]. The fact that hANT2 overexpression enhances the classic
cancer cell phenotype in HeLa cells, which, like the majority
of tumour-derived cells, have basal high levels of hANT2
expression and a predominant glycolytic metabolism, reveals
the importance of hANT2 in regulating cellular metabolism.
Thus, our data from overexpression studies demonstrate the
ability of the hANT2 isoform per se to induce the shift from oxi-
dative to glycolyticmetabolism andpromote cell growth. It has
been shown that hANT2 silencing is a successful strategy for
reducing breast cancer cell viability [19]. In our study, the
lack of clear effects of hANT2 knockdown on growth rate
could be explained by an insufficient reduction of hANT2
protein, despite effective knockdown at themRNA level. How-
ever, hANT2 silencing and the consequent decrease in the
glycolytic index did induce oxidative metabolism.
Overexpression of hANT3 in cultured cells precludes the
study of metabolic consequences of changes in hANT3 gene
expression owing to the proapoptotic effects of this isoform
[20]. Nevertheless, we were able to study hANT3 function by
silencing its expression. hANT3 knockdown markedly
slowed cell growth, an effect that seemed to be related to a
decrease in cellular ATP levels, owing to the inability of
hANT3-silencedHeLacells to compensate this energetic failure
by increasing the glycolytic metabolism. The simplest expla-
nation for the impairment in ATP levels by hANT3 silencing
is that hANT3 is essential for proper OXPHOS activity. The
results in HeLa cells are very surprising because cancer cells,
such as HeLa cells, are characterized by a very low oxidative
metabolism; thus, a priori they would not have been expected
to be dependent onOXPHOS and therefore on hANT3 activity.
But, as noted above, under our experimental conditions, cells
were near confluence and therefore more dependent on
hANT3. Collectively, our results seem to indicate that cancer
cells are dependent on hANT2 when proliferating at high
rates and on hANT3 when proliferation slows.
In addition to its metabolic and proliferative consequences,
hANT3 silencing induced the transcription of genes encoding
the cytokines TNF-a, IL6 andMCP-1, a response that is indica-
tive of the intense cellular perturbation produced by the
decrease in hANT3 expression. One possible explanation for
activation of an inflammatory response—an increase in ROS
production due to impaired mitochondrial activity [39,40]—
would seem to be ruled out by our demonstration that there
was no relationship between hANT3 knockdown-induced
cytokine expression and ROS production. Instead, the decrease
in ATP levels and induction of IL6 expression by the ATP
rsob.royalsocietypublishing.org
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13synthase inhibitor oligomycin suggest a direct relationship
between energy impairment by hANT3 silencing and the
induction of cytokine expression.
In summary, the mRNA expression of hANT isoforms is
differentially regulated in a cell- and condition-dependent
manner. In cells that are not fully responsive to growth
arrest, such as HeLa and HepG2 cells, expression of hANT3
mRNA was upregulated upon a shift in cellular metabolism
towards oxidation or cessation of cell growth. By contrast, in
cells fully capable of growth arrest, like SGBS preadipocytes,
hANT2 mRNA expression was downregulated under these
same conditions. The ANT glycolytic index closely correlated
with the metabolic/proliferative status of cells independent
of the hANT isoform actually undergoing regulation and
could be used as a predictor of the metabolic/proliferative
status of cells. Moreover, hANT3 is essential for cell growth
and its silencing results in energy impairment and a cellstress-like response. On the other hand, hANT2 by itself is
able to induce cell proliferation and shift cell metabolism
towards glycolysis altogether. Thus, cancer cells require both
hANT2 and hANT3 depending on their proliferation status:
hANT2 when cells proliferate at high rates and hANT3 when
proliferation slows.
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